Jenburkt Pharmaceuticals (BOM:524731) Total Liabilities: ₹290 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524731 Jenburkt Pharmaceuticals Ltd BOM:524731
81 GF Score
Price ₹1,078.00
GF Value ₹1,119.65
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Jenburkt Pharmaceuticals Total Liabilities?

Jenburkt Pharmaceuticals BOM:524731 -0.34% 81 Total Liabilities is ₹290 Mil as of Mar. 2026. GuruFocus rates BOM:524731 with a GF Score™ of 81/100 and a GF Value™ of ₹1,119.65 (Fairly Valued). The stock has 1 warning sign investors should review.

Jenburkt Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was ₹290 Mil.

Jenburkt Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 (₹261.87 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹289.72 Mil).

Jenburkt Pharmaceuticals's annual Total Liabilities increased from Mar. 2024 (₹201.59 Mil) to Mar. 2025 (₹244.09 Mil) and increased from Mar. 2025 (₹244.09 Mil) to Mar. 2026 (₹289.72 Mil).

Jenburkt Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Jenburkt Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jenburkt Pharmaceuticals Total Liabilities Chart

Jenburkt Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 255.67 194.22 201.59 244.09 289.72

Jenburkt Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 244.09 0.00 261.87 0.00 289.72
BOM:524731
81GF Score
Jenburkt Pharmaceuticals Ltd BOM:524731
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jenburkt Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Jenburkt Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=231.467+(18.395+39.862
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=290

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=2260.126-1970.402
=290

Jenburkt Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=231.467+(18.395+39.862
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=290

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2260.126-1970.402
=290

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹290 Mil mean?
Jenburkt Pharmaceuticals (BOM:524731) has a Total Liabilities of ₹290 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Jenburkt Pharmaceuticals and its competitors.
Is Jenburkt Pharmaceuticals' Total Liabilities too high?
Jenburkt Pharmaceuticals' current Total Liabilities is ₹290 Mil. Overall, Jenburkt Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jenburkt Pharmaceuticals' Total Liabilities compare to ZTS?
Jenburkt Pharmaceuticals' Total Liabilities of ₹290 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Jenburkt Pharmaceuticals and its competitors. Jenburkt Pharmaceuticals's current Total Liabilities is ₹290 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenburkt Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals (BOM:524731) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,119.65, compared to a current price of ₹1,078.00 — trading 3.7% below its estimated fair value. The current Total Liabilities is ₹290 Mil. Jenburkt Pharmaceuticals' overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Jenburkt Pharmaceuticals (BOM:524731), the current Total Liabilities is ₹290 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jenburkt Pharmaceuticals (BOM:524731) Overvalued in 2026?

Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be undervalued. The current stock price of ₹1,078.00 is trading 3.7% below its estimated GF Value™ of ₹1,119.65. GuruFocus considers Jenburkt Pharmaceuticals to be Fairly Valued.

Key valuation signals for BOM:524731:

  • Total Liabilities: ₹290 Mil
  • GF Value™: ₹1,119.65 vs. price of ₹1,078.00 (3.7% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the BOM:524731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jenburkt Pharmaceuticals Business Description

Address 93, Jayprakash Road, Nirmala Apartments, Andheri (West, Mumbai, MH, IND, 400058
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
81GF Score

Get the complete analysis for BOM:524731

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,078.00
Price
₹1,119.65
GF Value